Prokarium’s ZH9 is currently being developed as an intravesical treatment for preventing recurrences in non-muscle invasive bladder cancer. Credit: Aria sandi hasim/Shutterstock.

UK-based biopharmaceutical company Prokarium has received two Notices of Allowance from the US Patent and Trademark Office (USPTO).

The patents will aid in “strengthening its [the company’s] position in the bladder cancer field”.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Application no 17/752,707 pertains to the co-administration of Prokarium’s salmonella strains with immune checkpoint inhibitors, aimed at augmenting the therapeutic efficiency of these inhibitors.

Meanwhile, application no 18/559,543 encompasses a salmonella-based method for treating neoplastic diseases, which works by inducing an immune response coupled with targeted anti-tumour action.

Prokarium CEO Kristen Albright stated: “This patent bolsters our IP portfolio and, more importantly, creates a stronger foundation for our clinical programme in bladder cancer.

“Together, these innovations represent a major value driver for the company, strengthening our position to attract strategic partners and investors as we address large, underserved markets in cancer immunotherapy.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Prokarium’s investigational immunotherapy ZH9 is currently being developed as an intravesical treatment for preventing recurrences in non-muscle invasive bladder cancer.

The asset is being analysed in the PARADIGM-1 study, which is actively enrolling patients across multiple centres in the US.

In November 2023, the US Food and Drug Administration (FDA) granted clearance for the company’s investigational new drug (IND) application for the trial of ZH9.

In March 2024, Prokarium was awarded a UK Research and Innovation (UKRI) engineering biology grant, funded through the UKRI’s Technology Missions Fund and delivered by Innovate UK.

This grant is intended to expedite the development of the company’s Living Cures platform, which aims to transform precision medicine through off-the-shelf programmable therapeutics.

Leveraging the UKRI engineering biology grant, Prokarium also plans to commence the next phase of development to strengthen its position in the synthetic biology field.